Current management of patients with nonalcoholic fatty liver disease

References

• Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes. Rev. 11(6), 430–445 (2010).
   PubMed Web of Science ®Google Scholar
• Barrera F, George J. Non-alcoholic fatty liver disease: more than just ectopic fat accumulation. Drug Discov. Today 10(1–2), e47–e54 (2013).
   Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116(6), 1413–1419 (1999).
   PubMed Web of Science ®Google Scholar
• Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 172(7), 899–905 (2005).
   PubMed Web of Science ®Google Scholar
• Saglam K, Kilic R, Yilmaz MI, Gulec M, Baykal Y, Kutlu M. Insulin resistance in patients with steatohepatitis. Hepatogastroenterology 50(50), 456–459 (2003).
   PubMedGoogle Scholar
• Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 26(2), 98–106 (2000).
   PubMed Web of Science ®Google Scholar
• Comert B, Mas MR, Erdem H et al. Insulin resistance in non-alcoholic steatohepatitis. Dig. Liver Dis. 33(4), 353–358 (2001).
   PubMedGoogle Scholar
• Knobler H, Schattner A, Zhornicki T et al. Fatty liver--an additional and treatable feature of the insulin resistance syndrome. QJM 92(2), 73–79 (1999).
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8), 1844–1850 (2001).
   PubMed Web of Science ®Google Scholar
• Ong JP, Younossi ZM. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin. Liver Dis. 9(4), 617–634; vi (2005).
   PubMedGoogle Scholar
• Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin. Liver Dis. 8(3), 575–594(2004).
   PubMedGoogle Scholar
• Musso G, Gambino R, Cassader M. Need for a three-focused approach to nonalcoholic fatty liver disease. Hepatology 53(5), 1773; author reply 1774 (2011).
   PubMed Web of Science ®Google Scholar
• Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin. Gastroenterol. Hepatol. 10(6), 646–650 (2012).
   PubMed Web of Science ®Google Scholar
• Rafiq N, Bai C, Fang Y et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7(2), 234–238 (2009).
   PubMed Web of Science ®Google Scholar
• Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 59(10), 1410–1415 (2010).
   PubMed Web of Science ®Google Scholar
• Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129(1), 113–121 (2005).
   PubMed Web of Science ®Google Scholar
• Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 49(4), 608–612 (2008).
   PubMed Web of Science ®Google Scholar
• Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler. Thromb. Vasc. Biol. 25(5), 1045–1050 (2005).
   PubMed Web of Science ®Google Scholar
• McCullough AJ. Update on nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 34(3), 255–262 (2002).
   PubMed Web of Science ®Google Scholar
• Mulhall BP, Younossi ZM. Nonalcoholic Steatohepatitis. Curr. Treat. Options Gastroenterol. 7(6), 423–430 (2004).
   PubMedGoogle Scholar
• Ong JP, Elariny H, Collantes R et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes. Surg. 15(3), 310–315 (2005).
   PubMed Web of Science ®Google Scholar
• Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37(6), 1286–1292 (2003).
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim HJ, Lee KE et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med. 164(19), 2169–2175 (2004).
   PubMedGoogle Scholar
• Brudevold R, Hole T, Hammerstrom J. Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload. PLoS ONE 3(10), e3547(2008).
   Web of Science ®Google Scholar
• Bugianesi E, Manzini P, D'Antico S et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39(1), 179–187 (2004).
   PubMed Web of Science ®Google Scholar
• Fargion S, Mattioli M, Fracanzani AL et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96(8), 2448–2455 (2001).
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 114(4), 842–845 (1998).
   PubMed Web of Science ®Google Scholar
• Vuppalanchi R, Gould RJ, Wilson LA et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol. Int. (2011) (Epub ahead of print).
   Google Scholar
• Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123(3), 745–850 (2002).
   PubMed Web of Science ®Google Scholar
• Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 51(3), 433–445 (2009).
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Gramlich T, Liu YC et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod. Pathol. 11(6), 560–565 (1998).
   PubMed Web of Science ®Google Scholar
• Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94(9), 2467–2474 (1999).
   PubMed Web of Science ®Google Scholar
• Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum. Pathol. 35(2), 196–199 (2004).
   PubMed Web of Science ®Google Scholar
• Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46(2), 582–589 (2007).
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Jarrar M, Nugent C et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 18(11), 1430–1437 (2008).
   PubMed Web of Science ®Google Scholar
• Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346(16), 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 21(1), 17–26 (2001).
   PubMed Web of Science ®Google Scholar
• Tran TT, Changsri C, Shackleton CR et al. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J. Gastroenterol. Hepatol. 21(2), 381–383 (2006).
   PubMed Web of Science ®Google Scholar
• Minervini MI, Ruppert K, Fontes P et al. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J. Hepatol. 50(3), 501–510 (2009).
   PubMed Web of Science ®Google Scholar
• Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 8(12), 1114–1122 (2002).
   PubMed Web of Science ®Google Scholar
• Dhingra R, Sullivan L, Jacques PF et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 116(5), 480–488 (2007).
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Suzuki A, Guy C et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51(6), 1961–1971 (2010).
   PubMed Web of Science ®Google Scholar
• Maersk M, Belza A, Stodkilde-Jorgensen H et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am. J. Clin. Nutr. 95(2), 283–289 (2012).
   PubMed Web of Science ®Google Scholar
• Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36(6), 1349–1354 (2002).
   PubMed Web of Science ®Google Scholar
• Aller R, De Luis DA, Izaola O et al. Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with non alcoholic fatty liver disease. Eur. Rev. Med. Pharmacol. Sci. 16(3), 335–341 (2012).
   PubMed Web of Science ®Google Scholar
• Zain SM, Mohamed Z, Mahadeva S et al. Impact of leptin receptor gene variants on risk of non-alcoholic fatty liver disease and its interaction with adiponutrin gene. J. Gastroenterol. Hepatol. 28(5), 873–879 (2013).
   PubMed Web of Science ®Google Scholar
• Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30(6), 1356–1362 (1999).
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. 2(3), 262–265 (2004).
   PubMed Web of Science ®Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363(14), 1341–1350 (2010).
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Padovani R et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29(6), 1325–1330 (2006).
   PubMed Web of Science ®Google Scholar
• Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 28(4), 360–369 (2008).
   PubMed Web of Science ®Google Scholar
• Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 21(1), 27–41 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 23(2), 201–229 (2002).
   PubMed Web of Science ®Google Scholar
• Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J. Mol. Med. 80(11), 696–702 (2002).
   PubMed Web of Science ®Google Scholar
• Kaplan LM. Leptin, obesity, and liver disease. Gastroenterology 115(4), 997–1001 (1998).
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Pratt DS. Adiponectin--tipping the scales from NAFLD to NASH? Gastroenterology 128(2), 511–513; author reply 513(2005).
   PubMedGoogle Scholar
• National Institutes of Health. National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Publication No. 98–4083, Bethesda, MD, USA(1998).
   Google Scholar
• Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes care 27(8), 2057–2066 (2004).
   PubMed Web of Science ®Google Scholar
• Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 129(6), 1928–1936 (2005).
   PubMed Web of Science ®Google Scholar
• Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 35(1), 76–82 (2012).
   PubMed Web of Science ®Google Scholar
• Yamauchi R, Kobayashi M, Matsuda Y et al. Coffee and caffeine ameliorate hyperglycemia, fatty liver, and inflammatory adipocytokine expression in spontaneously diabetic KK-Ay mice. J. Agric. Food Chem. 58(9), 5597–5603 (2010).
   PubMed Web of Science ®Google Scholar
• Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J. Hepatol. 38(5), 681–687 (2003).
   PubMed Web of Science ®Google Scholar
• Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37(2), 343–350 (2003).
   PubMed Web of Science ®Google Scholar
• Shanab AA, Scully P, Crosbie O et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig. Dis. Sci. 56(5), 1524–1534 (2011).
   PubMed Web of Science ®Google Scholar
• Loguercio C, Federico A, Tuccillo C et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol. 39(6), 540–543 (2005).
   PubMed Web of Science ®Google Scholar
• Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am. J. Gastroenterol. 98(1), 175–179 (2003).
   PubMed Web of Science ®Google Scholar
• Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 35(1), 66–75 (2012).
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89(9), 4312–4319 (2004).
   PubMed Web of Science ®Google Scholar
• Karlsson HK, Hallsten K, Bjornholm M et al. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 54(5), 1459–1467 (2005).
   PubMed Web of Science ®Google Scholar
• Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39(1), 188–196 (2004).
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362(18), 1675–1685 (2010).
   PubMed Web of Science ®Google Scholar
• Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp. Diabetes Res. 2012, 716404(2012).
   PubMedGoogle Scholar
• Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J. Hepatol. 47(1), 135–141 (2007).
   PubMed Web of Science ®Google Scholar
• Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin. Liver Dis. 11(3), 597–613; vii (2007).
   PubMedGoogle Scholar
• Onofrei MD, Butler KL, Fuke DC, Miller HB. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 28(4), 522–529 (2008).
   PubMed Web of Science ®Google Scholar
• Hyogo H, Tazuma S, Arihiro K et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 57(12), 1711–1718 (2008).
   PubMed Web of Science ®Google Scholar
• Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin. Liver Dis. 28(4), 396–406 (2008).
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317(20), 1237–1245 (1987).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102(1), 21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Laurin J, Lindor KD, Crippin JS et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23(6), 1464–1467 (1996).
   PubMed Web of Science ®Google Scholar
• Scott R, O'Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32(3), 493–498 (2009).
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100(5), 1082–1090 (2005).
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc. Health Risk Manag. 5(1), 441–452 (2009).
   PubMedGoogle Scholar
• Sam AH, Salem V, Ghatei MA. Rimonabant: from RIO to Ban. J. Obes. 2011, 432607(2011).
   Google Scholar
• Patel PN, Pathak R. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am. J. Health. Syst. Pharm. 64(5), 481–489 (2007).
   PubMed Web of Science ®Google Scholar
• Ibanez P, Solis N, Pizarro M et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 22(6), 846–851 (2007).
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6), 2005–2023 (2012).
   PubMed Web of Science ®Google Scholar
• Klein EA, Thompson IM Jr, Tangen CM et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306(14), 1549–1556 (2011).
   PubMed Web of Science ®Google Scholar
• Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am. J. Gastroenterol. 106(1), 71–77 (2011).
   PubMed Web of Science ®Google Scholar
• Matafome P, Louro T, Rodrigues L et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab. Res. Rev. 27(1), 54–62 (2011).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39(3), 770–778 (2004).
   PubMed Web of Science ®Google Scholar
• Adams LA, Angulo P, Petz J, Keach J, Lindor KD. A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol. Int. 4(3), 628–633 (2010).
   PubMed Web of Science ®Google Scholar
• Klein S, Mittendorfer B, Eagon JC et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130(6), 1564–1572 (2006).
   PubMed Web of Science ®Google Scholar
• Mathurin P, Hollebecque A, Arnalsteen L et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137(2), 532–540 (2009).
   PubMed Web of Science ®Google Scholar
• Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric surgery on liver fibrosis. Obes. Surg. 22(7), 1044–1049 (2012).
   PubMed Web of Science ®Google Scholar
• Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am. J. Clin. Pathol. 104(1), 23–31 (1995).
   PubMed Web of Science ®Google Scholar
• Stratopoulos C, Papakonstantinou A, Terzis I et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes. Surg. 15(8), 1154–1160 (2005).
   PubMed Web of Science ®Google Scholar
• Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig. Dis. 28(1), 274–279 (2010).
   PubMed Web of Science ®Google Scholar
• Kral JG, Thung SN, Biron S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135(1), 48–58 (2004).
   PubMed Web of Science ®Google Scholar
• Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39(6), 1647–1654 (2004).
   PubMed Web of Science ®Google Scholar
• Jones Nielsen JD, Laverty AA, Millett C, Mainous AG 3rd, Majeed A, Saxena S. Rising obesity-related hospital admissions among children and young people in England: national time trends study. PLoS ONE 8(6), e65764(2013).
   Web of Science ®Google Scholar
• Hebert JR, Allison DB, Archer E, Lavie CJ, Blair SN. Scientific decision making, policy decisions, and the obesity pandemic. Mayo Clin. Proc. 88(6), 593–604 (2013).
   Google Scholar
• Deldin AR, Lee S. Role of physical activity in the treatment of nonalcoholic fatty liver disease in children and adolescents. Appl. Physiol. Nutr. Metab. 38(8), 805–812 (2013).
   PubMed Web of Science ®Google Scholar
• Bozic MA, Subbarao G, Molleston JP. Pediatric nonalcoholic Fatty liver disease. Nutr. Clin. Pract. 28(4), 448–458 (2013).
   PubMed Web of Science ®Google Scholar
• Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease. Nutr. Clin. Pract. 28(1), 101–111 (2013).
   PubMed Web of Science ®Google Scholar
• Ovchinsky N, Lavine JE. A critical appraisal of advances in pediatric nonalcoholic Fatty liver disease. Semin. Liver Dis. 32(4), 317–324 (2012).
   PubMed Web of Science ®Google Scholar
• Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr. 13, 40(2013).
   PubMedGoogle Scholar
• Raychaudhuri M, Sanyal D. Childhood obesity: determinants, evaluation, and prevention. Indian. J. Endocrinol. Metab. 16(Suppl. 2), S192–S194 (2012).
   PubMedGoogle Scholar
• Yin Z, Moore JB, Johnson MH, Vernon MM, Gutin B. The impact of a 3-year after-school obesity prevention program in elementary school children. Child Obes. 8(1), 60–70 (2012).
   PubMed Web of Science ®Google Scholar